What to Expect from Auxilium Pharmaceuticals
Auxilium Pharmaceuticals (NAS: AUXL) is expected to report Q4 earnings around Feb. 10. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Auxilium Pharmaceuticals's revenues will expand 135.3% and EPS will shrink -792.0%.
The average estimate for revenue is $172.5 million. On the bottom line, the average EPS estimate is $1.73.
Last quarter, Auxilium Pharmaceuticals chalked up revenue of $71.0 million. GAAP reported sales were 6.5% higher than the prior-year quarter's $66.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.21. GAAP EPS were -$0.21 for Q3 versus -$0.08 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.7%, 200 basis points worse than the prior-year quarter. Operating margin was -15.1%, 880 basis points worse than the prior-year quarter. Net margin was -14.8%, 870 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $394.3 million. The average EPS estimate is $1.62.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 131 members out of 185 rating the stock outperform, and 54 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Auxilium Pharmaceuticals a green thumbs-up, and 25 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $26.18.
- Add Auxilium Pharmaceuticals to My Watchlist.
The article What to Expect from Auxilium Pharmaceuticals originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.